This inventor holds 291 USPTO granted patents and 25 published patent applications, plus 6 CIPO patents and 7 EPO patents, primarily in RXR Agonists (CPC class A61K31-192). Top assignees: Allergan, Inc., Allergan Sales, Inc., Io Therapeutics, Inc.. Active years: 1988-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Inventors with similar research interests:
Location History:
- Missio Viejo, CA (US) (1995 - 1997)
- Mission Viego, CA (US) (1998)
- El Toro, CA (US) (1988 - 2000)
- Mission Voejo, CA (US) (2002)
- Mission Viejo, CA (US) (1994 - 2007)
- Laguna Hills, CA (US) (2001 - 2020)
- San Juan Capistrano, CA (US) (2018 - 2023)
- Spring, TX (US) (2023)
Company Filing History:
156 out of 2,287 
63 out of 228 
63 out of 72 
Years Active: 1988-2025
Areas of Expertise:
Title: Roshantha A Chandraratna: Innovating for Cancer Immunotherapy and Autoimmune Diseases
Introduction:
In the realm of medical innovation, Roshantha A Chandraratna, hailing from San Juan Capistrano, CA, has emerged as a prolific inventor and pioneer in the field of cancer immunotherapy and autoimmune disease treatments. With an impressive number of 287 patents under his name, Chandraratna has made significant contributions to medical science. This article delves into his latest patents, career highlights, collaborations, and his invaluable work in the field.
Latest Patents:
Chandraratna's latest patents include groundbreaking advancements in cancer immunotherapy and the treatment of autoimmune diseases. One notable patent involves the combination of CAR-modified immune cells with Retinoic Acid Receptor (RAR) and/or Retinoid X Receptor (RXR) active agents. This novel method aims to enhance cancer treatment by leveraging the immune system's own potential for fighting cancer.
Another recent patent sheds light on the treatment of autoimmune diseases using a combination of RXR agonists and thyroid hormones. This innovative approach presents promising therapeutic possibilities by targeting the underlying mechanisms of autoimmune conditions.
Career Highlights:
Throughout his illustrious career, Chandraratna has worked with esteemed companies such as Allergan, Inc. and Io Therapeutics, Inc. These collaborations have enabled him to bring his visionary ideas to life and translate them into practical solutions. His rich expertise has propelled him to the forefront of medical research and development, earning him respect within the industry.
Collaborations:
Chandraratna's relentless pursuit of innovation has led him to collaborate with numerous renowned scientists and researchers. Notable among his coworkers are Richard L Beard and Min Teng. These collaborations highlight Chandraratna's commitment to interdisciplinary research, leveraging diverse skill sets to tackle complex medical challenges.
Conclusion:
Roshantha A Chandraratna's impressive portfolio of patents and groundbreaking contributions in cancer immunotherapy and the treatment of autoimmune diseases have positioned him as a prominent figure in the field of medical innovation. His work demonstrates an unwavering commitment to improving patient outcomes and pushing the boundaries of medical science. As a master inventor and visionary, Chandraratna continues to inspire and shape the future of medicine with his pioneering ideas and collaborative approach.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile